The field of HCV has changed perhaps faster than any other field in medicine. The Guest Editors have strived to create an issue that is a state-of-the-art analysis of solutions to specific challenges faced in the United States and globally in implementing HCV elimination strategies. They believe that clinicians now have the tools and road maps needed to accomplish this goal. The clinical review articles in this issue accomplish that: Using Existing Health Care Infrastructure To Expand HCV Care; Creating A Reproducible Health Economic Model To Describe The Burden Of HCV And Cost Of Treatment In Any Country; The Best Uses Of Cost-Effectiveness Models In HCV; Increasing Access To HCV Care In Corrections; Cure As Prevention Strategies For HCV In People Who Inject Drugs; Australia Will Eliminate HCV – How It Works; New York Is The First State In The US To Develop An HCV Elimination Strategy; When HCV Diagnostics Are The Barrier To Care; Key Findings From The Checs HCV Cohort Study; Strategies To Reduce HCV Reinfection Rates In People Who Inject Drugs; Strategies To Reduce HCV Reinfection Rates In Men Who Have Sex With Other Men; The Value Of Curing HCV From A Payer’s Perspective; How To Expand Care Capacity In HCV; Strategies To Eliminate HCV In The HIV Coinfected Population; and The US Veteran’s Administration: Lessons Learned And Best Practices For HCV Elimination.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xiii 7. Preface - p. xv 8. Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings - p. 253 9. Elimination of Hepatitis C Virus in Australia: Laying the Foundation - p. 269 10. Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success - p. 281 11. Localized US Efforts to Eliminate Hepatitis C - p. 293 12. New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care - p. 313 13. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination - p. 323 14. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice - p. 347 15. Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs - p. 371 16. Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men - p. 395 17. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus–Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure - p. 407 18. Hepatitis C Virus Diagnosis and the Holy Grail - p. 425 19. A Guide to the Economics of Hepatitis C Virus Cure in 2017 - p. 447 20. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling - p. 461 21. The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System’s Perspective - p. 481
No hay muestra disponible
No hay ficha técnica disponible
The field of HCV has changed perhaps faster than any other field in medicine. The Guest Editors have strived to create an issue that is a state-of-the-art analysis of solutions to specific challenges faced in the United States and globally in implementing HCV elimination strategies. They believe that clinicians now have the tools and road maps needed to accomplish this goal. The clinical review articles in this issue accomplish that: Using Existing Health Care Infrastructure To Expand HCV Care; Creating A Reproducible Health Economic Model To Describe The Burden Of HCV And Cost Of Treatment In Any Country; The Best Uses Of Cost-Effectiveness Models In HCV; Increasing Access To HCV Care In Corrections; Cure As Prevention Strategies For HCV In People Who Inject Drugs; Australia Will Eliminate HCV – How It Works; New York Is The First State In The US To Develop An HCV Elimination Strategy; When HCV Diagnostics Are The Barrier To Care; Key Findings From The Checs HCV Cohort Study; Strategies To Reduce HCV Reinfection Rates In People Who Inject Drugs; Strategies To Reduce HCV Reinfection Rates In Men Who Have Sex With Other Men; The Value Of Curing HCV From A Payer’s Perspective; How To Expand Care Capacity In HCV; Strategies To Eliminate HCV In The HIV Coinfected Population; and The US Veteran’s Administration: Lessons Learned And Best Practices For HCV Elimination.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xiii 7. Preface - p. xv 8. Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings - p. 253 9. Elimination of Hepatitis C Virus in Australia: Laying the Foundation - p. 269 10. Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success - p. 281 11. Localized US Efforts to Eliminate Hepatitis C - p. 293 12. New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care - p. 313 13. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination - p. 323 14. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice - p. 347 15. Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs - p. 371 16. Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men - p. 395 17. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus–Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure - p. 407 18. Hepatitis C Virus Diagnosis and the Holy Grail - p. 425 19. A Guide to the Economics of Hepatitis C Virus Cure in 2017 - p. 447 20. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling - p. 461 21. The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System’s Perspective - p. 481
No hay muestra disponible
No hay ficha técnica disponible
